Thiazolidinediones for Nonalcoholic Steatohepatitis — Promising but Not Ready for Prime Time

Publisher Website
Google Scholar
Abstract
Mostly unrecognized before 1980, nonalcoholic fatty liver disease now affects all fields of clinical medicine and is the most common form of chronic liver disease in the United States.1 The prevalence of this disorder is expected to increase with the epidemic of obesity and type 2 diabetes mellitus. Its prevalence in non-Western countries is also increasing,2 in large part because of globalization of the Western diet. Data based on ultrasonographic studies and serum enzyme measurements indicate that the prevalence of nonalcoholic fatty liver disease in the general U.S. population is approximately 30%.1,3 This suggests that there may be as . . .